I respectfully disagree to an extent. Yes BLA will be a catalyst when it happens. But I am expecting to see 50 patients enrolled in the severe trial inside if 2 weeks. This starts the clock ticking for the interim review by FDA. (50 patients at 2 weeks)

It is y belief that this data will be enough for them to grant us an approval. If current trends hold the data will be impossible to ignore.